Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Sarcoma 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Squamous Non-small Cell Lung Cancer 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Carcinoma 1Histiocytoma, Malignant Fibrous 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Colonic Neoplasms 1Chondrosarcoma 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Doxorubicin 3spartalizumab 1nilotinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1envafolimab 1Trabectedin 1TQ-B3525 1Radiotherapy 1Proton Therapy 1Nivolumab 1Neoadjuvant Therapy 1Ipilimumab 1Immune Checkpoint Inhibitors 1Ifosfamide 1Heavy Ion Radiotherapy 1Gelclair 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Chondrosarcoma × envafolimab × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡